Antonella Isacchi

Discovery of drug mode of action and drug repositioning from transcriptional responses

Francesco Iorio, Roberta Bosotti, Emanuela Scacheri et al. · Proceedings of the National Academy of Sciences · 2010 · 852 citations · Full text

Life Sciences, Bioinformatics, Pharmacology +16

Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death

Paola Magnaghi, Roberto D’Alessio, Barbara Valsasina et al. · Nature Chemical Biology · 2013 · 383 citations

Life Sciences, Cell Biology, Molecular Biology +10

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

FAT: a novel domain in PIK-related kinases

Roberta Bosotti, Antonella Isacchi, Erik L. L. Sonnhammer · Trends in Biochemical Sciences · 2000 · 307 citations

Life Sciences, Biochemistry, Molecular Biology +10

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Maria Menichincheri, Elena Ardini, Paola Magnaghi et al. · Journal of Medicinal Chemistry · 2016 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17